asparaginase

Type: Keyphrase
Name: asparaginase
First reported Apr 23 2014 - Updated Apr 23 2014 - 1 reports

Report Summarizes Leukemia Gene Therapy Study Findings from KIIT University

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting out of Bhubaneswar, India , by NewsRx editors, research stated, "L-Asparaginase-II from Escherichia ... [Published HispanicBusiness.com - Apr 23 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

New Findings in Acute Lymphoblastic Leukemia Described from University of Crete

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Oncology have been published. According to news reporting originating from Iraklion, Greece , by NewsRx correspondents, research stated, "Increased levels of asparagine synthetase ... [Published HispanicBusiness.com - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

ERYTECH PHARMA : Secures Orphan Drug Designation by the FDA for ERY-ASP in Acute Myeloid Leukemia

Erytech Pharma , a French biopharmaceutical company that develops treatments for acute leukemia and other oncology indications with unmet medical needs, announced that its lead product GRASPA/ERY-ASP has been granted Orphan Drug Designation by the U.S. ... [Published 4 Traders - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Why Childhood Cancer Survival Rates Have Increased

Advanced chemotherapy and personalized treatment have boosted survival rates for childhood cancersApril 15, 2014 / Author: Sheryl Wood / Reviewed by: Joseph V. Madia, MDRate This ArticleAverage RatingYour Rating(dailyRx News) With increasing survival ... [Published Daily Rx - Apr 15 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

ERYTECH receives FDA orphan drug designation for treatment of leukemia

ERYTECH Pharma, a French biopharmaceutical company, has received orphan drug designation for its GRASPA/ERY-ASP1 from the FDA for the treatment of acute myeloid leukemia, or AML. ERY-ASP, in Europe know as GRASPA, is a new enzyme formulation of L-asparaginase, ... [Published Individual.com - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

ERYTECH PHARMA : Receives Orphan Drug Designation by the FDA for ERY-ASP in Acute Myeloid Leukemia

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Regulatory News : ERYTECH Pharma (Paris:ERYP) ( Euronext Paris : FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other ... [Published 4 Traders - Apr 10 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 2 reports

ERYTECH adds a new product candidate to its tumor starvation development portfolio

Details Category: Proteins and Peptides Published on Wednesday, 09 April 2014 08:58 Hits: 15 ERYTECH encapsulates a new enzyme, methionine-γ-lyase (MGL), in red blood cellsFurther broadening of the application of its proprietary technology in on ... [Published PipelineReview - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

ERYTECH PHARMA : Gets Orphan Drug Designation by the FDA for ERY-ASP in Acute Myeloid Leukemia

Erytech Pharma , a French biopharmaceutical company that develops treatments for acute leukemia and other oncology indications with unmet medical needs, announced that its lead product GRASPA/ERY-ASP has been granted Orphan Drug Designation by the U.S. ... [Published 4 Traders - Apr 08 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Erytech gets FDA orphan drug status for ERY-ASP in acute myeloid leukaemia

French biopharmaceutical firm Erytech Pharma has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its lead product GRASPA/ERY-ASP for treatment of acute myeloid leukaemia (AML), an aggressive form of blood can ... [Published Pharmaceutical Technology - Apr 03 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has ... [Published News-Medical.Net - Apr 02 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 2 reports

Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For..

Severe VOD, one of the most serious early complications in HSCT therapy, is associated with multi-organ failure and is fatal in over 80% of patients.2"The commercial availability of Defitelio as the first medicine licensed for the treatment of sVOD in ... [Published ADVFN UK - Mar 31 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Are Biotech Stocks Located in Ireland Top Buyout Candidates?

St. Patrick’s Day may have come and gone for this year, but some of the biotechnology stocks that are domiciled in Ireland might just be getting ready for the party. Horizon Pharmaceuticals has announced that it plans to acquire privately held Vidara ... [Published 24/7 Wall St - Mar 19 2014]

Quotes

According to the news editors, the research concluded: "These highly desirable attributes of these variants could significantly advance asparaginase therapy of leukemia in the future."
...According to news reporting originating from Iraklion, Greece , by NewsRx correspondents, research stated, "Increased levels of asparagine synthetase (ASNS), an enzyme producing intracellular asparagine, have been implicated in the development of asparaginase resistance. The aim of this study was to assess ASNS mRNA and protein expression in bone marrow cell populations of children with acute lymphoblastic leukemia (ALL)."
...very pleased by the granting of this additional Orphan Drug Designation" said Dr Yann Godfrin , co-founder and Chief Scientific Officer of Erytech. "We have been encouraged by the results from our work in Acute Lymphoblastic Leukemia, and are committed to further clinical evaluation of the product in other indications of high unmet need. Acute Myeloid Leukemia and solid tumor cancers are investigated to develop a safe and effective therapy, providing a superior treatment outcome. Orphan Drug Status provides certain benefits that can support us in achieving this goal."
...very pleased by the granting of this additional Orphan Drug Designation" said Dr Yann Godfrin, co-founder and Chief Scientific Officer of ERYTECH. "We have been encouraged by the results from our work in Acute Lymphoblastic Leukemia, and are committed to further clinical evaluation of the product in other indications of high unmet need."

More Content

All (22) | News (21) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Report Summarizes Leukemia Gene Therapy Study F... [Published HispanicBusiness.com - Apr 23 2014]
New Findings in Acute Lymphoblastic Leukemia De... [Published HispanicBusiness.com - Apr 17 2014]
ERYTECH PHARMA : Secures Orphan Drug Designatio... [Published 4 Traders - Apr 16 2014]
Why Childhood Cancer Survival Rates Have Increased [Published Daily Rx - Apr 15 2014]
ERYTECH receives FDA orphan drug designation fo... [Published Individual.com - Apr 11 2014]
ERYTECH PHARMA : Receives Orphan Drug Designati... [Published 4 Traders - Apr 10 2014]
ERYTECH adds a new product candidate to its tum... [Published PipelineReview - Apr 09 2014]
ERYTECH adds a new product candidate to its tum... [Published BusinessWeek - Apr 09 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
ERYTECH PHARMA : Gets Orphan Drug Designation b... [Published 4 Traders - Apr 08 2014]
Erytech gets FDA orphan drug status for ERY-ASP... [Published Pharmaceutical Technology - Apr 03 2014]
FDA grants orphan drug designation to ERYTECH’s... [Published News-Medical.Net - Apr 02 2014]
Younger Patients With ALL Could Bypass a Transp... [Published OncLive - Apr 01 2014]
Jazz Pharmaceuticals And Gentium Announce Europ... [Published ADVFN UK - Mar 31 2014]
JAZZ PHARMACEUTICALS : And Gentium Announce Eur... [Published 4 Traders - Mar 31 2014]
Jazz Pharmaceuticals Breaks Ground On New Manuf... [Published Longitude Capital - Mar 26 2014]
LifeSci Advisors Launches Coverage of Erytech [Published HispanicBusiness.com - Mar 24 2014]
Are Biotech Stocks Located in Ireland Top Buyou... [Published 24/7 Wall St - Mar 19 2014]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - Mar 02 2014]
Jazz Pharmaceuticals Announces Acquisition From... [Published PR Newswire - Jan 13 2014]
Methods and compositions for targeting agents i... [Published PharmCast - Jan 05 2014]
NPPA revises prices of 63 more formulation pack... [Published PharmaBiz - Nov 09 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
Jazz Pharmaceuticals Announces Acquisition From... [Published PR Newswire - Jan 13 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.